10-K: Yubo International Biotech Limited Reports Full Year 2023 Results, Highlights Stem Cell Bank Progress

Yubo International Biotech Limited's 2023 annual report details increased revenue driven by new health management services, alongside ongoing development of its endometrial stem cell bank.

Summary

• Yubo International Biotech Limited, a U.S. holding company operating primarily through its subsidiary Platinum, released its annual report for the fiscal year ended December 31, 2023.
• The company reported a significant increase in sales to $604,676 in 2023, compared to $104,283 in 2022, primarily due to the launch of new health management and maintenance services.
• Cost of goods sold also increased to $185,491 in 2023 from $51,631 in 2022, reflecting the higher sales volume.
• Operating expenses rose to $1,613,891 in 2023, up from $1,257,875 in 2022, due to increases in occupancy and depreciation costs.
• The company's net loss decreased slightly to $1,195,083 in 2023 from $1,204,994 in 2022, due to the increased revenue.
• Yubo Beijing is focused on the research and development of endometrial stem cells and is building a stem cell repository.
• The company is developing light application products under the VIVCELL brand, including respiratory atomization products, cell basidiomycetes compound drinks, and various skincare and personal care items.
• Yubo Beijing plans to complete the first stage of building its stem cell bank by December 2024 and expects it to be fully operational by 2028.
• The company's financial statements include a going concern warning due to recurring operating losses and negative working capital of $2,670,210 as of December 31, 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive revenue growth and progress on the stem cell bank, the company's ongoing losses, negative working capital, and going concern warning create significant concerns. The regulatory risks and reliance on third-party manufacturers also contribute to a negative outlook.

Positives

• The company experienced a substantial increase in revenue year-over-year, driven by new service offerings.
• Gross profit saw a significant improvement, indicating better profitability on sales.
• The company is making progress on its stem cell bank project, with the first stage expected to be completed by the end of 2024.
• Yubo Beijing has a diverse product line under the VIVCELL brand, targeting various health and personal care needs.
• The company has secured an invention patent related to endometrial collection, which is a key technology for its stem cell bank.

Negatives

• The company continues to operate at a loss, with a net loss of $1,195,083 in 2023.
• Operating expenses increased significantly, offsetting some of the revenue gains.
• The company has a negative working capital of $2,670,210 as of December 31, 2023.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• Yubo Beijing is past due on its headquarters lease obligation in the amount of RMB2,270,783.

Risks

• The company's VIE structure in China carries significant regulatory risks, including potential penalties or loss of control.
• There are uncertainties regarding the interpretation and application of PRC laws related to the VIE structure.
• The company faces risks associated with cybersecurity, data privacy, and data security compliance in China.
• The medical industry in China is highly regulated, and changes in regulations could affect the approval and commercialization of Yubo Beijing's products.
• The company relies on third-party manufacturers, which poses risks related to supply chain disruptions and quality control.
• The company faces significant competition in the medical industry in China.
• The company may need additional capital and may not be able to obtain it on acceptable terms.
• The company's common stock is not listed on a major exchange and is subject to penny stock rules, which may limit liquidity.

Future Outlook

Yubo Beijing plans to build a first-class stem cell storage facility and expand its product line to include medical-grade cell therapeutic products. The company expects to complete the first stage of building the stem cell bank by December 2024 and to be fully operational by 2028. The company also plans to expand its biological experience center stores into a nationwide franchise.

Management Comments

• Management believes Yubo Beijing's existing technology and leadership position in stem cell processing will drive significant future growth for the company.
• Management expects that operating its own commercial stem cell manufacturing and storage facilities will provide it with enhanced control of material supply, enable the more rapid implementation of process changes, and allow for better long-term cost margins.

Industry Context

The document indicates that the stem cell industry in China is competitive, with approximately 77,990 companies engaged in stem cell-related activities. However, Yubo Beijing believes it has a unique core technology in endometrial stem cell storage, which differentiates it from competitors. The company's main competitor is VCANBIO CELL&GENE, which had revenue of approximately RMB1.6 billion in 2022.

Comparison to Industry Standards

• The document mentions VCANBIO CELL&GENE as a key competitor, with a revenue of approximately RMB1.6 billion in 2022, which provides a benchmark for comparison.
• The document notes that there are approximately 77,990 companies engaged in stem cell collection and storage, research and development, and application in China, indicating a highly competitive market.
• The company's focus on endometrial stem cell storage is presented as a unique offering, suggesting a potential competitive advantage over companies with broader stem cell focuses.
• The company's integrated approach, combining stem cell storage with light application products, is presented as a competitive advantage, but there are no specific industry standards mentioned for this model.

Related Party Transactions

• Yubo Beijing has entered into a Joint Research and Development Agreement with Beijing Zhenxigu Medical Research Center (L.P.), which is controlled by a shareholder of Yubo Beijing.
• Yubo Beijing has entered into an Entrustment Technical Service Agreement with Beijing Zhenhuikang Biotechnology Co., Ltd., which is an affiliate of a shareholder of Yubo Beijing.
• The company had certain short-term borrowings from its directors totaling $1,859,276 as of December 31, 2023.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may be impacted by any changes in the company's product offerings or service quality.
• Suppliers may face risks related to the company's ability to pay its obligations.
• Creditors face risks related to the company's ability to repay its debts.

Next Steps

• Yubo Beijing plans to complete the first stage of building its stem cell bank by December 2024.
• The company intends to raise additional capital in 2024.
• Yubo Beijing plans to expand its biological experience center stores into a nationwide franchise.
• The company will continue to develop and expand its current product line.

Key Dates

Keywords

stem cell, endometrial stem cells, biotech, China, VIVCELL, healthcare products, medical devices, regulatory, VIE, manufacturing